Study Information

Alliance Study ID: CALGB-40105

NCT Study ID (ClinicalTrials.gov): NCT00045591

Alliance Committee: Breast Cancer

Disease or Cancer Type: Breast Cancer

Alliance Study Chair: Charles L. Shapiro, MD

Status: TERMINATED


Study Description

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. It is not yet known which regimen of celecoxib is more effective in treating breast cancer.

PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of celecoxib in treating women who have metastatic or recurrent breast cancer

Related Publications

For publications related to this and other clinical trials, visit the Alliance Publications Application.

Data Sources & Contacts

Related Alliance Trials

Related News